Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose cytarabine plus thalidomide for untreated adult Langerhans cell histiocytosis
ChiCTR2600123531Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cytarabine and thalidomide in Langerhans cell histiocytosis (LCH), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Event-free survival (EFS). Started Apr 2026; status: recruiting.
02
Drugs
cytarabinethalidomide
03
Conditions
Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on ChiCTR2600123531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123531.